CN121313845A - 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 - Google Patents

用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Info

Publication number
CN121313845A
CN121313845A CN202510670682.5A CN202510670682A CN121313845A CN 121313845 A CN121313845 A CN 121313845A CN 202510670682 A CN202510670682 A CN 202510670682A CN 121313845 A CN121313845 A CN 121313845A
Authority
CN
China
Prior art keywords
group
carbon atoms
cell
tripterine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510670682.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·德扎尔基西安
N·诺伊瑟克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taga Biomedical Co
Original Assignee
Taga Biomedical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taga Biomedical Co filed Critical Taga Biomedical Co
Publication of CN121313845A publication Critical patent/CN121313845A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN202510670682.5A 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 Pending CN121313845A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662350258P 2016-06-15 2016-06-15
US62/350,258 2016-06-15
PCT/CA2017/000151 WO2017214709A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs
CN201780049693.5A CN109803664A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780049693.5A Division CN109803664A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Publications (1)

Publication Number Publication Date
CN121313845A true CN121313845A (zh) 2026-01-13

Family

ID=60663810

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510670682.5A Pending CN121313845A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法
CN201780049693.5A Pending CN109803664A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780049693.5A Pending CN109803664A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Country Status (9)

Country Link
US (2) US11446265B2 (https=)
EP (1) EP3471733B1 (https=)
JP (3) JP7009463B2 (https=)
CN (2) CN121313845A (https=)
AU (1) AU2017285486B2 (https=)
CA (1) CA3027682A1 (https=)
DK (1) DK3471733T3 (https=)
ES (1) ES2992544T3 (https=)
WO (1) WO2017214709A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055817A1 (en) * 2017-09-14 2019-03-21 The Regents Of The University Of California EX VIVO CONSERVATION AND EXPANSION OF STEM CELLS
US11446312B2 (en) 2018-02-14 2022-09-20 Societe Des Produits Nestle S.A. Compounds that modulate von Willebrand factor levels and their use in the treatment of blood disorders
HUE065501T2 (hu) 2018-08-20 2024-05-28 Janssen Pharmaceutica Nv A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
US20220023345A1 (en) * 2020-07-22 2022-01-27 Caladrius Biosciences, Inc. Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
WO2022212878A1 (en) * 2021-04-01 2022-10-06 The Regents Of The University Of California Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases
CN118634317B (zh) * 2024-08-16 2024-10-22 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1112181C (zh) 2000-05-26 2003-06-25 北京大学 雷公藤属植物提取物在制备预防和治疗神经系统疾病药上的应用
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
WO2008013985A2 (en) * 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
US20080044390A1 (en) * 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
EP2152252A4 (en) 2006-11-13 2010-06-02 Univ Columbia SELECTIVE PROTEASOMIC INHIBITORS FOR THE TREATMENT OF DIABETES
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CN101288671B (zh) 2008-04-17 2010-12-01 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
WO2010077642A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
CN101756956A (zh) 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
CA3044998A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Also Published As

Publication number Publication date
JP2024019483A (ja) 2024-02-09
JP2019523784A (ja) 2019-08-29
US11446265B2 (en) 2022-09-20
US20210169830A1 (en) 2021-06-10
US12419849B2 (en) 2025-09-23
AU2017285486A1 (en) 2019-02-07
AU2017285486B2 (en) 2023-04-27
ES2992544T3 (es) 2024-12-13
WO2017214709A8 (en) 2018-12-13
CN109803664A (zh) 2019-05-24
EP3471733B1 (en) 2024-08-07
US20230024103A1 (en) 2023-01-26
WO2017214709A1 (en) 2017-12-21
JP7009463B2 (ja) 2022-01-25
EP3471733A1 (en) 2019-04-24
JP2022062037A (ja) 2022-04-19
DK3471733T3 (da) 2024-10-14
CA3027682A1 (en) 2017-12-21
EP3471733A4 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
US12419849B2 (en) Reagents, compositions and methods for improving viability and function of cells, tissues and organs
Lim et al. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model
Lee et al. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes
Angoulvant et al. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury
Chou et al. Stem cells and kidney regeneration
Pan et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats
Tian et al. Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation
Motawi et al. The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis
Amer et al. Role of adipose tissue derived stem cells differentiated into insulin producing cells in the treatment of type I diabetes mellitus
Hendijani et al. Human Wharton's jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin
AU2007243221A1 (en) Methods for treating diabetes
Wang et al. Exosomes from adipose-derived mesenchymal stem cells can attenuate liver injury caused by minimally invasive hemihepatectomy combined with ischemia-reperfusion in minipigs by modulating the endoplasmic reticulum stress response
Oyar et al. The therapeutical effects of damage-specific stress induced exosomes on the cisplatin nephrotoxicity IN VIVO
Tousoulis et al. Infusion of lin−/sca-1+ and endothelial progenitor cells improves proinflammatory and oxidative stress markers in atherosclerotic mice
Schoenfeld et al. The existence of myocardial repair: mechanistic insights and enhancements
Yang et al. Neovascularization and cardiomyocytes regeneration in acute myocardial infarction after bone marrow stromal cell transplantation: comparison of infarct-relative and noninfarct-relative arterial approaches in swine
Gopinath et al. Human umbilical cord blood derived stem cells repair doxorubicin-induced pathological cardiac hypertrophy in mice
Ellis et al. Adipose stem cell secretome markedly improves rodent heart and hiPSC-derived cardiomyocyte recovery from cardioplegic transport solution exposure
Long et al. Effects of octreotide on activated pancreatic stellate cell-induced pancreas graft fibrosis in rats
HK40008604A (zh) 用於改善细胞、组织和器官的活力和功能的试剂、组合物和方法
KR101648915B1 (ko) 줄기세포의 응집방지 방법 및 그 조성물
Clancy Autologous cells for renal allograft repair
Malik et al. Regeneration potential of bone marrow-derived mesenchymal stromal cells lysate for H2O2 (In-Vitro) injured cells
KR20190037020A (ko) 줄기세포 활성화 유도제 스크리닝 방법
Gonella Role of Liver Stem Cell-derived Extracellular Vesicles on ischemia-reperfusion injury in a murine liver experimental model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination